Medicare's New $50 GLP-1 Weight Loss Drug Program: Who Qualifies, What's Covered, and How to Get Started

Written by the physicians at Trinity Family Medicine — Dr. Casey Dean, DO & Dr. Kathryn Kline, MD, Board-Certified Family Medicine Physicians. Last medically reviewed: June 2026.

GLP-1 weight loss medications like Wegovy and Zepbound can cost $1,000 to $1,600 a month without insurance — prices that put them out of reach for most people. But starting July 1, 2026, the Medicare GLP-1 Bridge program changes that. Eligible Medicare beneficiaries can now get FDA-approved weight loss medications for just $50 a month.

For the estimated 14 million Medicare beneficiaries living with obesity, this is the first time the federal government has offered meaningful access to these drugs specifically for weight loss. Here is what you need to know — from physicians who prescribe GLP-1 medications every day and who will handle the prior authorization (the approval paperwork your doctor submits) for you.

Quick Summary: Key Facts at a Glance

What Is the Medicare GLP-1 Bridge Program?

Under federal law, Medicare Part D plans cannot cover medications prescribed solely for weight loss. That means even though drugs like Wegovy and Zepbound are FDA-approved for treating obesity, Medicare has historically refused to pay for them when the primary purpose is weight management.

The Medicare GLP-1 Bridge is a time-limited demonstration program created by the Centers for Medicare & Medicaid Services (CMS) to close that gap. It runs from July 1, 2026 through December 31, 2027, and it operates separately from your regular Part D drug benefit. Think of it as a temporary workaround: CMS is using its authority to test whether giving Medicare patients access to these medications improves health outcomes and reduces long-term healthcare costs.

There are two important cost details to understand. First, the $50 copay applies to each 30-day supply, and your Part D deductible does not apply — you pay $50 from day one, not after meeting a deductible. Second, the $50 copay does not count toward your TrOOP (true out-of-pocket) costs. That means it will not help you reach the catastrophic coverage phase of your Part D plan any faster.

Which Medications Are Covered?

The Medicare GLP-1 Bridge covers three FDA-approved weight loss medications. All FDA-approved doses and gradual dose increases are included, so your doctor can start you at a lower dose and work up to the full dose — which is standard practice — and every step is covered at the same $50 copay.

Wegovy (semaglutide) is available as a once-weekly injection or a once-daily oral tablet. Wegovy was the first GLP-1 approved specifically for chronic weight management, and the oral tablet received FDA approval in December 2025. It works by mimicking a natural hormone called GLP-1 that regulates appetite and food intake. In clinical trials, patients lost an average of 15–17% of their body weight over about 68 weeks.

Zepbound KwikPen (tirzepatide) is a once-weekly injection that targets two hormones — GLP-1 and GIP — which may provide slightly greater weight loss than semaglutide alone. Clinical trials showed average weight loss of 15–21% depending on the dose. An important detail: only the KwikPen multi-dose pen formulation is covered. Single-dose vials and single-dose pens of Zepbound are not covered under the Bridge program.

Foundayo (orforglipron) is an oral daily pill and one of the newest options. Unlike semaglutide, orforglipron is a small molecule rather than a peptide, which means it does not require refrigeration and may be easier to manufacture at scale. It represents a next-generation approach to GLP-1 therapy for weight loss.

Covered GLP-1 Medications at a Glance

Who Qualifies? The Three Eligibility Tiers

To qualify for the Medicare GLP-1 Bridge, you must be enrolled in a Medicare Part D prescription drug plan — either a standalone PDP or a Medicare Advantage plan with drug coverage (MA-PD). You must also meet one of three clinical eligibility tiers based on your body mass index (BMI) and medical history.

Tier 1: BMI of 35 or Higher — No Additional Conditions Required

If your BMI is 35 or above at the time you start GLP-1 therapy, you qualify automatically. No additional diagnoses are needed. For reference, a person who is 5'6" and weighs 217 pounds has a BMI of approximately 35.

Tier 2: BMI of 30 or Higher with Specific Comorbidities

If your BMI is between 30 and 34.9, you qualify if you also have one or more of these conditions: heart failure with preserved ejection fraction (HFpEF) — a type of heart failure where the heart pumps normally but is too stiff to fill properly — uncontrolled hypertension (high blood pressure that has not reached target despite treatment), or chronic kidney disease at stage 3a or higher.

Tier 3: BMI of 27 or Higher with Cardiovascular or Metabolic History

If your BMI is between 27 and 29.9, you qualify if you have a history of one or more of these: prediabetes as defined by the American Diabetes Association, a previous heart attack (myocardial infarction), a previous stroke, or symptomatic peripheral artery disease (PAD) — reduced blood flow to the legs causing pain with walking.

Your doctor will verify your BMI and review your medical history during your visit. If your BMI was measured at a recent appointment, that measurement can be used — you do not necessarily need a new one.

Who Does NOT Qualify? Important Exclusions

This is where the program catches many people off guard. If you already receive a GLP-1 medication through your regular Medicare Part D plan for another covered condition, you are not eligible for the Bridge program — even if you also want to use it for weight loss.

Specifically, you are excluded if you are already receiving a GLP-1 through Part D for any of these conditions:

The logic is straightforward: those conditions are already covered indications under Part D, so your existing plan should be paying for your GLP-1. The Bridge program was created specifically for beneficiaries who cannot access these drugs through any other Medicare pathway — people who need them for weight loss alone.

If you have type 2 diabetes and are currently taking a GLP-1 for that condition, talk to your Part D plan about your coverage options. If you do not have diabetes but meet the BMI and clinical criteria above, you are likely a candidate for the Bridge.

The Lifestyle Modification Requirement

The FDA labels for Wegovy, Zepbound, and Foundayo all state that these medications should be used alongside a healthier diet and more physical activity — not as a standalone solution. The Medicare GLP-1 Bridge requires that your doctor confirm you are receiving the medication alongside structured lifestyle changes — including nutrition guidance and a physical activity plan.

In practical terms, this means your doctor will discuss dietary recommendations and exercise goals during your visit and document that counseling in your medical record. This is not a separate program you need to enroll in. It is a standard part of any responsible weight loss treatment plan, and your physician will address it as part of your care.

How Prior Authorization Works — Step by Step

The Medicare GLP-1 Bridge requires prior authorization before your first prescription can be filled. Here is exactly what the process looks like when you work with Trinity Family Medicine:

What This Costs Compared to Paying Out of Pocket

To put the $50 Medicare GLP-1 Bridge copay in perspective, here is what these medications typically cost:

Without any coverage, Wegovy runs approximately $1,300 to $1,600 per month at retail. The Zepbound KwikPen — the only formulation covered by the Bridge — costs approximately $1,000 to $1,500 per month at retail depending on the dose. Even manufacturer direct-pay programs — like Novo Nordisk's NovoCare or Lilly's self-pay vials — still cost $149 to $499 per month.

Through the Medicare GLP-1 Bridge, you pay $50 per month for any covered medication at any dose. Combined with a Trinity Family Medicine telehealth visit at $74.99 for the initial consultation, your total first-month cost is approximately $125 — for medications that would otherwise cost ten times that amount.

When to Talk to Your Doctor — and How Trinity Family Medicine Can Help

If you are a Medicare beneficiary with a BMI of 27 or higher and have been wanting to try a GLP-1 weight loss medication, the Bridge program may be the most affordable path available to you. You do not need to see a specialist — board-certified family medicine physicians are fully qualified to evaluate your eligibility, prescribe these medications, and manage your care.

At Trinity Family Medicine, we offer telehealth visits to patients anywhere in Texas. We will review your medical history, verify your eligibility, and handle the entire prior authorization process on your behalf. You do not need to navigate CMS paperwork, call Humana's central processor, or figure out which forms to submit. That is our job.

We also provide the structured lifestyle modification counseling the program requires — nutrition guidance and physical activity recommendations tailored to your health status and goals. And because we are a direct-pay practice, you do not need a referral or insurance approval for the visit itself.

Book a weight loss consultation or call us at 817-932-4022.

Frequently Asked Questions

The Bottom Line

The Medicare GLP-1 Bridge program is a historic first — the first time Medicare has offered meaningful access to weight loss medications for beneficiaries who need them. If you are enrolled in Medicare Part D and meet the BMI and clinical criteria, you can get Wegovy, Zepbound, or Foundayo for $50 a month starting July 1, 2026. The program runs through December 2027, and your family medicine doctor can handle the entire process — including prior authorization — through a simple telehealth visit.

References